Annual

Report

2021

We would like to take this opportunity to thank you, dear shareholders, for your trust and unwavering support over the past years. Although recent global events have disrupted the environment in which we operate, rest assured that innovation and value creation remain at the centre of our focus. We look forward to achieving further major accomplishments in 2022.

Leon Van Rompay

Chief Executive Officer

2021 Highlights

R&D Pipeline

Estetrol in Women’s Health and Beyond

Contraception

First estetrol-based product launched

Menopause

Positive top-line results Phase III

Neuroprotection, Wound healing

Launch of Clinical Program on neuroprotection

Complex Therapeutics

Contraception

Launched in Europe, Canada & Chile

Menopause & Osteoporosis

Commercialized in about 40 countries

Breast & prostate cancer

Full global Licensing rights

Mithra CDMO

Brand new manufacturing facility fully dedicated to fill & finish production of complex liquid injectables and biologicals in vials, pre-filled syringes or cartridges

Partnership with the Belgian biotech ExeVir for the manufacturing of innovative Covid-19 treatments at Mithra CDMO’s new Injectable Facility

In 2021, 28% green energy produced by 5000 solar panels

252
collaborators
87
new hiring
56
Women
44
Men

Key Figures

Revenues

22.7
million

First product sales Estelle®

13.4
million

Still around

290
million cash

to be collected for Estelle® out-licensing
and sales related milestones

ESG Strategy

Conscious of our role and influence on society, we have decided to launch our social responsibility strategy in 2021 through the creation of a Sustainability Committee and the selection of commitment axes and sustainable development objectives defined by the United Nations.

Patients

Planet

People

Ethics
and Integrity

Women
Empowerment

Investor Relations

Benoît Mathieu
+32 (0) 473 35 80 18
investorrelations@mithra.com
Rue Saint-Georges 5
4000 Liège – Belgium

Follow us

Annual

Report

2021